REGENXBIO

Nasdaq: RGNX · SEC EDGAR filings

Results on file1
Average 24h move−38.15%across 1 result with a complete 24h price
1 resultREGENXBIO
Met endpoint

RGX-202

Phase 3 Duchenne Muscular Dystrophy

REGENXBIO RGNX

24h stock move −38.15%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.